Previous studies have shown that DDR2 is involved in the communication between tumor cells and stromal cells in breast cancer, and its selective extracellular small molecule inhibitor (WRG-2) can delay tumor invasion and migration by inhibiting receptor–ligand interactions53. Here, DDR2 is linked to breast carcinoma.